MEB and PJH have developed subunit vaccines against SARS and MERS coronavirus infections. They are involved in the process of developing a vaccine against SARS-CoV-2. DBC is a scientific advisor and holds intellectual property in Atropos Therapeutics, LLC.
Dr. Thomas Monath has joined Mymetics as consulting Chief Medical Officer. Dr. Monath has devoted his nearly 30-year career to the fight against infectious disease through his work in the military, corporate, academic and investment sectors. Mymetics Selects RSV Program as Lead Development Program from ... www.yahoo.com/news/mymetics-selects-rsv-program... Aug 21, 2012 · Dr. Thomas Monath has joined Mymetics as consulting Chief Medical Officer. Dr. Monath has devoted his nearly 30-year career to the fight against infectious disease through his work in the military...
FI-RSV, but not RSV-MPLA virosomes, primed for increases in expression of Th2 cytokines IL-4, IL-5, IL-13, and Th1 cytokine IL-1b, 6 hour-5 days after infection. By contrast, RSV-MPLA virosomes induced IFN-? transcripts to similar levels as induced by live virus. Animals vaccinated with FI-RSV, but not RSV-MPLA virosomes showed alveolitis, with prominent neutrophil influx and peribronchiolar and perivascular infiltrates. Conclusion: These results show that RSV-MPLA virosomes represent a safe and immunogenic vaccine candidate that warrants evaluation in a clinical setting.
Market Data 
Markets 
AI
